Four EU countries secure access to Oxford vaccine as AZ’s dose commitments exceed 2B

AstraZeneca’s agreement with the Inclusive Vaccines Alliance, announced Saturday, is the latest in a string of deals for access to its COVID-19 vaccine. The U.K. pharma has now committed to provide several global organizations and countries with a total 2.1 billion doses of AZD1222, which it licensed from the University of Oxford.

AstraZeneca plc (LSE:AZN; NYSE:AZN) will supply IVA with up to 400 million doses of the vaccine, formerly ChAdOx1 nCoV-19, at no profit. Deliveries are expected to begin by year-end...